rezatapopt Clinical Trials (2026): 3 Studies for Acute Myeloid Leukemia & Advanced Malignant Neoplasm
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 rezatapopt clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Acute Myeloid Leukemia & Advanced Malignant Neoplasm) and 338 total planned enrollment. 3 rezatapopt clinical trials are actively recruiting at 32 U.S. sites across 18 states. Most recent activity: NCT06616636 (Aug 2029).
Where to Participate: All rezatapopt Trial Sites in the U.S. (32 sites across 18 states)
Every actively recruiting rezatapopttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California Irvine Chao Family Comprehensive Cancer Center | Irvine92868 | NCT04585750 | Map |
| CA | UCLA Jonsson Comprehensive Cancer Center | Los Angeles90024 | NCT04585750 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT04585750 | Map |
| CO | HealthOne Denver | Denver80237 | NCT07372625 | Map |
| CO | Rocky Mountain Cancer Center | Denver80218 | NCT04585750 | Map |
| CT | Yale Cancer Center | New Haven06519 | NCT04585750 | Map |
| DE | Medical Oncology Hematology Consultants | Newark19713 | NCT04585750 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Center | Miami33136 | NCT04585750 | Map |
| FL | Florida Cancer Specialists | Orlando32827 | NCT07372625 | Map |
| FL | Florida Cancer Specialists South | Port Charlotte33980 | NCT04585750 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT04585750 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04585750 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT04585750 | Map |
| NY | Memorial Sloan Kettering | New York10065 | NCT04585750 | Map |
| NC | Duke University | Durham27705 | NCT04585750 | Map |
| OH | The Cleveland Clinic Taussig Cancer Center | Cleveland44195 | NCT04585750 | Map |
| OK | University of Oklahoma | Oklahoma City73104 | NCT04585750 | Map |
| OR | Oregon Health & Science University (OHSU) | Portland97210 | NCT04585750 | Map |
| PA | Abramson Cancer Center of the University of Pennsylvania | Philadelphia19104 | NCT04585750 | Map |
| PA | WellSpan York Cancer Center | York17403 | NCT04585750 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT04585750 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07372625 | Map |
| TX | New Experimental Therapeutics - NEXT Oncology | Austin78705 | NCT04585750 | Map |
| TX | SCRI at Mary Crowley | Dallas75230 | NCT07372625 | Map |
| TX | UT Southwest Simmons Cancer Center | Dallas75390 | NCT04585750 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT04585750 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06616636 | Map |
| TX | New Experimental Therapeutics of San Antonio - NEXT Oncology | San Antonio78229 | NCT04585750 | Map |
| TX | NEXT Oncology | San Antonio78229 | NCT07372625 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT04585750 | Map |
| WA | University of Washington, Fred Hutchinson Cancer Center | Seattle98109 | NCT04585750 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53705 | NCT04585750 | Map |
rezatapopt clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 2 | 2 |
| P1/P2 | 1 | 1 |
Recruiting rezatapopt clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | P1 | Myelodysplastic Syndrome | 24 | Jan 2025 |
| NCT07372625 | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | P1 | TP53 Y220C Mutation | 14 | Feb 2026 |
| NCT04585750 | PYNNACLEThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | P1/P2 | Advanced Solid Tumor | 300 | Oct 2020 |
rezatapopt clinical trials by indication
TP53 Y220C Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07372625 | — | P1 | recruiting | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. |
Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06616636 | — | P1 | recruiting | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04585750 | PYNNACLE | P1/P2 | recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
All rezatapopt trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | P1 | recruiting | 24 | M.D. Anderson Cancer Center | Jan 2025 | |
| NCT07372625 | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | P1 | recruiting | 14 | PMV Pharmaceuticals, Inc | Feb 2026 | |
| NCT04585750 | PYNNACLE | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | P1/P2 | recruiting | 300 | PMV Pharmaceuticals, Inc | Oct 2020 |
rezatapopt clinical trials: frequently asked questions
- How many rezatapopt clinical trials are there?
- 3 rezatapopt clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are rezatapopt clinical trials recruiting in 2026?
- Yes — 3 rezatapopt trials are actively recruiting in 2026, with 32 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is rezatapopt being studied for?
- rezatapopt is being studied for Acute Myeloid Leukemia, Advanced Malignant Neoplasm, Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer and 29 more. The trials are grouped by indication on this page.
- What phase is rezatapopt in?
- rezatapopt clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors rezatapopt clinical trials?
- The lead sponsor across the most rezatapopt trials is PMV Pharmaceuticals, Inc, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming rezatapoptas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: